Achievements of Indians in Science & Technology: Focus on Biosimilars and Biopharma SHAKTI Vision

Recently, the Indian Pharmacopoeia Commission (IPC) organized a national conference in Bengaluru focusing on the quality and safety of biosimilars, a key component of India's biopharmaceutical strategy. This is crucial for the UPSC as it relates to GS Paper 3 on Science and Technology. Last Updated: 17-09-2026

Key Facts About Achievements of Indians in Science & Technology

• Indian Pharmacopoeia Commission (IPC) organized a two-day conference on biosimilars.
• The conference aimed to enhance India's biopharmaceutical ecosystem through quality, innovation, and regulatory excellence.
• Indian Pharmacopoeia Reference Substance (IPRS) for Enoxaparin Sodium was released for bioassays.
• Biosimilars are highly similar versions of approved biological medicines.
• The Biopharma SHAKTI Vision was announced in the Union Budget 2025-26 with an outlay of ₹10,000 crore over five years.
• The initiative aims to establish three new National Institutes of Pharmaceutical Education and Research (NIPERs) and upgrade seven existing ones.

India's Biopharmaceutical Growth

The focus on biosimilars is a strategic move to bolster India's position in the global biopharmaceutical market. By enhancing research and clinical infrastructure, India aims to reduce its dependence on imports and promote domestic manufacturing. This aligns with India's broader economic goals of self-reliance and innovation-led growth, contributing significantly to the healthcare sector.

UPSC Relevance

• GS Paper 3: Science and Technology - Developments and their applications and effects in everyday life.
• Prelims: Questions could focus on the definition and benefits of biosimilars, and the role of IPC.
• Mains: Analytical themes could include the impact of biosimilars on healthcare costs and access, and India's strategy in biopharma.
• Essay Paper: Topics on innovation in healthcare and self-reliance in pharmaceuticals.

FAQ Section

• What is the Biopharma SHAKTI Vision?
  The Biopharma SHAKTI Vision is an initiative announced in the Union Budget 2025-26, aiming to strengthen India's biopharmaceutical ecosystem with a ₹10,000 crore investment over five years.
• Why are biosimilars important?
  Biosimilars provide safe and effective treatment options for various medical conditions, improving patient access and potentially reducing healthcare costs.
• What are the key features of the IPC's recent conference?
  The conference focused on enhancing the quality and safety of biosimilars, fostering collaboration among regulators, industry, academia, and research organizations.